Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Diabetic kidney disease (DKD) is a major public health challenge with an increasing incidence/prevalence worldwide, in tandem with the rising incidence/prevalence of Type 2 diabetes mellitus (T2DM). It is the leading cause of kidney failure globally and has significant morbidity and mortality. The glomerular filtration rate (GFR) is considered the best index of kidney function and is most widely estimated using serum creatinine, which is fraught with limitations. Cystatin C has been proposed as a more accurate marker than serum creatinine for early detection of kidney impairment due to its specific properties. Validating eGFR formulae is problematic among diabetic patients. However, cystatin C-containing formulae have been accepted. Hence, this study aimed at assessing and comparing kidney function in T2DM patients using eGFRcys, eGFRcr, and combined eGFRcr-cys equations in a predominantly black African population.
This hospital-based cross-sectional study involved 200 adult type 2 DM patients aged ≥ 18 years recruited consecutively from the Endocrinology clinic of the tertiary hospital, following informed consent. Relevant data were obtained using a pre-tested questionnaire. A detailed physical examination was done. Blood sample was collected for serum cystatin C and creatinine. eGFR was calculated using the 2012 CKD-EPI eGFRcys, 2021 CKD-EPI eGFRcr, and the 2021 combined CKD-EPI eGFRcr-cys equations. Cystatin C levels > 1.12mg/L were considered diagnostic of CKD. Patients with acute kidney injury, including those with thyroid gland dysfunction, autoimmune diseases, Liver diseases, malignancies, congestive heart failure, HIV/AIDS, Current smokers, those on steroids, and pregnant women were excluded. Laboratory investigations were carried out at the hospital's laboratory. Data were analyzed using SPSS version 23.
A total of 98(49%) males and 102(51%) females were recruited. The study mean age was 56.60 ± 11.96 (58.34 ± 12.22 = males, 54.93 ± 11.51= females) years.
The mean eGFR calculated using eGFRcr, eGFRcys, and eGFRcr-cys were 71.57 ± 32.16, 66.19 ± 32.27, and 70.26 ± 32.05, respectively. The prevalence of eGFR < 60 mL/min/1.73m2 using eGFRcr, eGFRcys, and eGFRcr-cys was 42.0%, 54.0%, and 47.5% respectively. The eGFRcys equation had the highest sensitivity of 90.0%, specificity of 100.0%, positive predictive value (PPV) of 100.0%, negative predictive value (NPV) of 86.9%, and an accuracy of 94.0%, eGFRcr equation had the lowest sensitivity, specificity, PPV, NPV, and accuracy.
The prevalence of eGFR< 60 mL/min/1.73m2 among T2DM patients was high irrespective of the eGFR equation used. Thus, community-based awareness campaigns, screening, early detection and intervention, plus better diabetic care are advocated. Cystatin C-based (eGFRcys and eGFRcr-cys) equations appear to be accurate and more sensitive in identifying African T2DM patients with eGFR decline.
